- Home
- PGEN vs PRQR Comparison
PGEN vs PRQR Comparison
Compare PGEN & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGEN
- PRQR
- Stock Information
- Founded
- PGEN 1998
- PRQR 2012
- Country
- PGEN United States
- PRQR Netherlands
- Employees
- PGEN N/A
- PRQR N/A
- Industry
- PGEN Biotechnology: Pharmaceutical Preparations
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- PGEN Health Care
- PRQR Health Care
- Exchange
- PGEN Nasdaq
- PRQR Nasdaq
- Market Cap
- PGEN 493.0M
- PRQR 232.8M
- IPO Year
- PGEN N/A
- PRQR 2014
- Fundamental
- Price
- PGEN $3.59
- PRQR $1.99
- Analyst Decision
- PGEN Buy
- PRQR Strong Buy
- Analyst Count
- PGEN 5
- PRQR 8
- Target Price
- PGEN $7.50
- PRQR $8.88
- AVG Volume (30 Days)
- PGEN 10.4M
- PRQR 378.7K
- Earning Date
- PGEN 11-13-2025
- PRQR 11-06-2025
- Dividend Yield
- PGEN N/A
- PRQR N/A
- EPS Growth
- PGEN N/A
- PRQR N/A
- EPS
- PGEN N/A
- PRQR N/A
- Revenue
- PGEN $4,340,000.00
- PRQR $20,129,184.00
- Revenue This Year
- PGEN $253.63
- PRQR N/A
- Revenue Next Year
- PGEN $699.64
- PRQR N/A
- P/E Ratio
- PGEN N/A
- PRQR N/A
- Revenue Growth
- PGEN N/A
- PRQR 8.65
- 52 Week Low
- PGEN $0.65
- PRQR $1.07
- 52 Week High
- PGEN $5.23
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- PGEN 49.90
- PRQR 37.36
- Support Level
- PGEN $3.89
- PRQR $2.21
- Resistance Level
- PGEN $5.23
- PRQR $2.50
- Average True Range (ATR)
- PGEN 0.34
- PRQR 0.15
- MACD
- PGEN -0.16
- PRQR -0.03
- Stochastic Oscillator
- PGEN 6.82
- PRQR 4.63
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.